American Superconductor Q2 Earnings Beat Estimates, Revenues Rise Y/Y
ZACKS· 2025-11-07 00:31
Key Takeaways American Superconductor posted Q2 earnings of 20 cents per share, beating the consensus estimate by 33.3%.Revenues rose 20.9% year over year to $65.86M, led by strength in Grid and Wind segments. Q3 revenues are projected between $65M and $70M, with earnings expected near 14 cents per share.American Superconductor Corporation ((AMSC) reported second-quarter fiscal 2025 earnings of 20 cents per share, which beat the Zacks Consensus Estimate by 33.3%. AMSC’s second-quarter earnings declined 25.9 ...
Bloomin' Brands (BLMN) Reports Q3 Earnings: What Key Metrics Have to Say
ZACKS· 2025-11-07 00:31
For the quarter ended September 2025, Bloomin' Brands (BLMN) reported revenue of $928.81 million, down 10.6% over the same period last year. EPS came in at -$0.03, compared to $0.21 in the year-ago quarter.The reported revenue represents a surprise of +3.18% over the Zacks Consensus Estimate of $900.17 million. With the consensus EPS estimate being -$0.12, the EPS surprise was +75%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to de ...
Here's What Key Metrics Tell Us About Papa John's (PZZA) Q3 Earnings
ZACKS· 2025-11-07 00:31
For the quarter ended September 2025, Papa John's (PZZA) reported revenue of $508.15 million, up 0.3% over the same period last year. EPS came in at $0.32, compared to $0.43 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $525.88 million, representing a surprise of -3.37%. The company delivered an EPS surprise of -20%, with the consensus EPS estimate being $0.40.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ho ...
Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025
Globenewswire· 2025-11-07 00:31
Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025 Compelling kidney function data from VIVIAD Phase 2b study presented in late-breaking poster at ASN kidney week, the world’s premier nephrology meetingVIVIAD analyses continue to support varoglutamstat’s potential in kidney disease, and consistently provide further evidence for a beneficial impact on kidney function based on its proposed mechanism of action Halle (Saale) / ...
GDEN Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Golden Entertainment, Inc. is Fair to Shareholders
Businesswire· 2025-11-07 00:31
On behalf of Golden shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of- pocket payment of our legal fees or expenses. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instr ...
Aspo Plc: Share repurchase 6.11.2025
Globenewswire· 2025-11-07 00:30
Aspo Plc ANNOUNCEMENT 6.11.2025 Aspo Plc: Share repurchase 6.11.2025 In the Helsinki Stock Exchange Trade date 6.11.2025 Bourse trade Buy Share ASPO Amount 1 300SharesAverage price/ share 6,8077EURTotal cost 8 850,01EUR Aspo Plc now holds a to ...
Zealand Pharma conference call on November 13 at 2pm CET (8am ET) to present third quarter 2025 financial results
Globenewswire· 2025-11-07 00:30
Press Release – No. 15 / 2025 Zealand Pharma conference call on November 13 at 2pm CET (8am ET) to present third quarter 2025 financial results Copenhagen, Denmark, November 6, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on November 13, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the third q ...
Zealand Pharma conference call on November 13 at 2pm CET (8am ET) to present third quarter 2025 financial results
Globenewswire· 2025-11-07 00:30
Press Release – No. 15 / 2025 Zealand Pharma conference call on November 13 at 2pm CET (8am ET) to present third quarter 2025 financial results Copenhagen, Denmark, November 6, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on November 13, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the third q ...
Zalando Q3 Revenues Rise Rapidly on Back of About You Purchase
Yahoo Finance· 2025-11-07 00:30
Revenues at Zalando, one of Europe’s largest online fashion retailing platforms, rose 26.5 percent over the third quarter and totaled 3.02 billion euros. The German company’s gross merchandise value, or GMV, also rose 21.6 percent to 4.21 billion euros in the three months through September. Zalando sees GMV, which measures how much inventory the platform has moved, as a key indicator; it is usually higher than company revenue. More from Sourcing Journal For the first nine months of 2025, Zalando was able ...
喀麦隆当选总统保罗·比亚宣誓就职
央视新闻· 2025-11-07 00:29
△保罗·比亚(资料图) 比亚现年92岁,自1982年起连续执政至今。 喀麦隆总统选举采取全民直选方式,得票最高者当选。总统每届任期7年,可无限连任。(总台记者 李雪薇) 当地时间11月6日,喀麦隆总统保罗·比亚在该国议会举行就职仪式,正式开启其第八个总统任期。 10月12日,喀麦隆举行总统选举,包括比亚在内的12名候选人参与角逐。根据官方公布的计票结果,比亚以54%的得票率胜 出,赢得连任。 ...